Preoperative Chemoradiotherapy for Esophageal Cancer

To the Editor: Van Hagen et al. (May 31 issue) 1 found, after a median follow-up of almost 4 years, that preoperative chemoradiotherapy with weekly carboplatin and paclitaxel followed by surgery significantly improved disease-free and overall survival as compared with surgery alone in patients with...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 367; no. 9; pp. 872 - 874
Main Authors Power, Derek G, O'Sulleabhain, Criostoir, Murphy, Thomas J, Matzdorff, Axel C, Julià, David, Gómez, Núria, Codina-Cazador, Antoni, van Hagen, Pieter, van Lanschot, Joseph J.B, van der Gaast, Ate
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 30.08.2012
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer
Carboplatin
Chemoradiotherapy
Chemoradiotherapy, Adjuvant
Chemotherapy
Clinical trials
Esophageal Neoplasms - surgery
Esophageal Neoplasms - therapy
Esophagogastric Junction
Esophagus
Female
Health risk assessment
Humans
Male
Paclitaxel
Platinum
Surgery
Thromboembolism
Thrombosis
Toxicity
Online AccessGet full text

Cover

More Information
Summary:To the Editor: Van Hagen et al. (May 31 issue) 1 found, after a median follow-up of almost 4 years, that preoperative chemoradiotherapy with weekly carboplatin and paclitaxel followed by surgery significantly improved disease-free and overall survival as compared with surgery alone in patients with esophageal or esophagogastric-junction cancer. Although postoperative complications were higher than expected, the data on mortality and overall toxicity compare very favorably with those reported in previous trials. In our view, this study represents a new standard of care for this patient group. The association between upper gastrointestinal cancers and thrombosis is established. 2 Platinum-based chemotherapy is also . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc1207702